Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaFrederick L. Locke, Jason R. Westin, David B. Miklos et al.|New England Journal of Medicine|2021Cited by 1.6k
Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R. Westin, Frederick L. Locke, Olalekan O. Oluwole et al.|New England Journal of Medicine|2023Cited by 437
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphomaFrederick L. Locke, Jérôme Galon, Christina To et al.|Nature Medicine|2024Cited by 114
A Multicenter Phase II Study of AMG 337 in Patients with <i>MET</i>-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other <i>MET</i>-Amplified Solid TumorsEric Van Cutsem, David Cunningham, Bogusława Karaszewska et al.|Clinical Cancer Research|2018Cited by 73
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Saran Vardhanabhuti et al.|Blood Cancer Discovery|2023Cited by 49